[HTML] sciencedirect.com

[HTML][HTML] Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance of pancreatic cancer

Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
被引用次数：37 相关文章
[PDF] researchgate.net

[PDF][PDF] Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer

Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - researchgate.net
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

[引用][C] Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance of pancreatic cancer

Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - cir.nii.ac.jp
Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance
of pancreatic cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …

Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer.

Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer

Z Gu, Y Du, X Zhao, C Wang - Cancer letters - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …